Intradermal administration of novel particulate Chlamydia trachomatis vaccine candidates drives protective immune responses.

Autor: Huynh DT; Abera Bioscience AB, Uppsala, Sweden; Group of Molecular Microbiology, Amsterdam Institute for Life and Environment (A-LIFE), Vrije Universiteit, Amsterdam, the Netherlands., Nolfi E; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands., Guleed S; Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Medfai L; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands., Wolf N; Abera Bioscience AB, Uppsala, Sweden., Uijen RF; Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., de Jonge MI; Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., van Ulsen P; Group of Molecular Microbiology, Amsterdam Institute for Life and Environment (A-LIFE), Vrije Universiteit, Amsterdam, the Netherlands., Dietrich J; Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Luirink J; Abera Bioscience AB, Uppsala, Sweden; Group of Molecular Microbiology, Amsterdam Institute for Life and Environment (A-LIFE), Vrije Universiteit, Amsterdam, the Netherlands., Sijts AJAM; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. Electronic address: e.j.a.m.sijts@uu.nl., Jong WSP; Abera Bioscience AB, Uppsala, Sweden. Electronic address: wouter.jong@aberabio.com.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Nov; Vol. 180, pp. 117563. Date of Electronic Publication: 2024 Oct 13.
DOI: 10.1016/j.biopha.2024.117563
Abstrakt: Chlamydia trachomatis causes the most prevalent bacterial sexually transmitted infection worldwide. Its complex lifecycle and the lack of appropriate antigen delivery vehicles make it difficult to develop an effective C. trachomatis vaccine. Recently, bacterial protein bodies (PBs) have emerged as promising bioparticles for vaccine antigen delivery. By developing a PB-tag for translational fusion, we were able to induce the aggregation of recombinant antigens expressed in Escherichia coli into PBs. Here, we investigated the immunogenicity and efficacy of PBs containing either the C. trachomatis MOMP-derived CTH522-SP or HtrA antigen in mice. Intradermal administration of c-di-AMP-adjuvanted PB-CTH522-SP and PB-HtrA vaccines, produced in an LPS-detoxified E. coli strain, induced antigen-specific cellular immunity, as measured by significant release of IFN-γ and IL17a in draining cervical lymph node and splenic cell cultures. Moreover, significant induction of HtrA-specific IFN-γ expressing CD4 + and CD8 + T cells was detected in the spleens. While immunization with the two PB vaccines led to prominent levels of specific antibodies in both serum and vaginal compartments, only antiserum against PB-CTH522-SP exhibited C. trachomatis-specific neutralization activity. Importantly, intradermal immunization with PB-CTH522-SP significantly reduced bacterial counts following C. trachomatis genital challenge. These data highlight the potential of the PB-based platform for the development of C. trachomatis vaccines.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Wouter S. P. Jong reports financial support was provided by Abera Bioscience AB. Dung T. Huynh reports financial support was provided by Abera Bioscience AB. Natascha Wolf reports financial support was provided by Abera Bioscience AB. Joen Luirink reports financial support was provided by Abera Bioscience AB. Wouter S.P. Jong has patent #WO2018138316 pending to Abera Bioscience AB. Joen Luirink has patent #WO2018138316 pending to Abera Bioscience AB. Marien I. de Jonge is a member of the Advisory board of Abera Bioscience AB If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
(Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: